.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,731,986

« Back to Dashboard

Claims for Patent: 7,731,986

Title:Therapeutic foam
Abstract: A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurised canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimising the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed.
Inventor(s): Wright; David Dakin Iorwerth (Buckinghamshire, GB), Harman; Anthony David (Oxfordshire, GB), Robinson; Nikki (Uxbridge, GB), Hodges; Garry (Middlesex, GB), Kadar; Adil (Middlesex, GB), Moggridge; Geoffrey D. (Cambridge, GB), Van Liew; Hugh (Barnstable, MA)
Assignee: BTG International Ltd. (London, GB)
Application Number:10/522,527
Patent Claims: 1. A foam comprising a liquid phase and a gas phase wherein the liquid phase comprises at least one sclerosing agent and the gas phase consists essentially of gaseous nitrogen present in an amount ranging from 0.01% to 0.8% by volume and a physiologically acceptable gas mixture comprising 10 to 90% vol/vol carbon dioxide with the remaining gas oxygen.

2. The foam of claim 1, wherein the gaseous nitrogen is present in an amount ranging from 0.01% to 0.7%.

3. The foam of claim 1, wherein the gaseous nitrogen is present in an amount ranging from 0.01% to 0.6%.

4. The foam of claim 1, wherein the foam has a density less than 0.25 g/cm and half life of greater than 100 secs.

5. The foam of claim 1, wherein the half life is at least 120 seconds.

6. The foam of claim 1, wherein the half life is at least 150 seconds.

7. The foam of claim 1, wherein the half life is at least 180 seconds.

8. The foam of claim 1, wherein the density ranges from 0.07 to 0.22 g/ml.

9. The foam of claim 1, wherein the density ranges from 0.07 to 0.19 g/ml.

10. The foam of claim 1, wherein the density ranges from 0.07 to 0.16 g/ml.

11. The foam of claim 1, wherein the density ranges from 0.08 to 0.14 g/ml.

12. The foam of claim 1, wherein the at least one sclerosing agent is chosen from polidocanol, glycerol and sodium tetradecyl sulphate.

13. The foam of claim 1, wherein the at least one sclerosing agent is polidocanol.

14. The foam of claim 13, wherein the polidocanol is present in a concentration ranging from 0.5 to 4% vol/vol in the liquid phase.

15. A canister, the contents of which consist of a liquid component and a gas component, maintained at above atmospheric pressure, wherein: the liquid phase comprises at least one sclerosing agent and the gas phase consists essentially of gaseous nitrogen present in an amount ranging from 0.01% to 0.8% by volume and a physiologically acceptable gas mixture comprising 10 to 90% vol/vol carbon dioxide with the remaining gas oxygen.

16. The canister of claim 15, further comprising a foam generating element with at least one aperture formed therein, the at least one aperture having maximum dimensions ranging from 0.1 to 200 micron.

17. The canister of claim 16, wherein the at least one aperture has maximum dimensions ranging from 1 to 50 micron.

18. The canister of claim 17, wherein the at least one aperture has maximum dimensions ranging from 2 to 30 micron.

19. The canister of claim 18, wherein the at least one aperture has maximum dimensions ranging from 3 to 10 micron.

20. The canister of claim 19, wherein the at least one aperture has maximum dimensions of about 5 micron.

21. The canister of claim 17, wherein the at least one aperture has a maximum dimension of 3 to 10 micron, and wherein the physiologically acceptable gas mixture is from 1 to 40% carbon dioxide and the remaining gas is oxygen.

22. The canister of claim 17, wherein the physiologically acceptable gas mixture is from 10 and 30% carbon dioxide gas and the remaining gas is oxygen.

23. A method of making a canister of claim 15 comprising: (a) flushing the canister with a gas mixture essentially comprising the other physiological acceptable gas; (b) introducing the at least one sclerosing agent sclerosing agent into the canister either before or after step (a); (c) pressurizing the canister to a first predetermined pressure above atmospheric pressure from a source of the other physiological acceptable gas whose level of nitrogen contamination is between 0.0001% and 0.5%; (d) partially exhausting the contents of the canister, followed by re-pressurizing the canister from the same or a different source of the other physiologically acceptable gas whose level of nitrogen contamination is between 0.0001% and 0.5%.

24. The method of claim 23, wherein the pressure in the canister is maintained at or above the surrounding atmospheric pressure.

25. A method for angiologic treatment comprising injecting the foam as described in claim 1 into vessels to be treated.

26. The method of claim 25 comprising having a patient breathe oxygen or an oxygen enriched atmosphere for a predetermined period prior to injecting the foam.

27. The method for phlebologic treatment comprising injecting the foam as described in claim 1 into vessels to be treated.

28. The method of claim 27 comprising having a patient breathe oxygen or an oxygen enriched atmosphere for a predetermined period prior to injecting the foam.

29. The method of claim 28, wherein substantially the entire greater saphenous vein of one leg of a human patient is treated by a single injection of foam.

30. The method of claim 29, wherein the single injection uses an amount ranging from 10 ml to 50 ml.

31. The method of claim 30, wherein the single injection uses an amount ranging from 10 ml to 40 ml.

32. The method of claim 31, wherein the single injection uses an amount ranging from 15 ml to 30 ml.

33. The foam of claim 1, wherein 50% or more by number of gas bubbles of 25 .mu.m diameter and over present in the foam are of no more than 200 .mu.m diameter and at least 95% by number of gas bubbles of 25 .mu.m diameter and over are of no more than 280 .mu.m diameter.

34. The foam of claim 33, wherein at least 50% by number of gas bubbles of 25 .mu.m diameter and over present in the foam are of no more than 150 .mu.m diameter and at least 95% by number of gas bubbles of 25 .mu.m diameter and over are of no more than 250 .mu.m diameter.

35. The foam of claim 1 wherein none of the gas bubbles of the foam is of greater than 500 .mu.m diameter.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc